Planta Med 2023; 89(15): 1442-1443
DOI: 10.1055/a-2177-7634
Consensus Statement
Consensus Statement

Consensus Statement on the Outcome of a Workshop on Paediatric Phytotherapy: Rationalising Optimal Dosing for Use in Children by Real-World Data

Andreas Hensel
1   Foundation Plants for Health, Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Germany
Rudolf Bauer
2   Foundation Plants for Health; Institute of Pharmaceutical Sciences, Department of Pharmacognosy, University of Graz, Austria
Michael Heinrich
3   Society of Medicinal Plant and Natural Products Research, UCL School of Pharmacy, University College London, United Kingdom
Karin Kraft
4   Gesellschaft für Phytotherapie, University Medicine Rostock, Germany
› Author Affiliations

A Project of the Foundation Plants for Health (PfH), Gesellschaft für Phytotherapie (GPT), and Society for Medicinal Plant and Natural Product Research (GA)

Herbal medicinal products (HMPs) play an important role in paediatric medicine. Based on the strong impact of HMPs in clinical practice, the costs of such products are covered by the statutory health insurance of some European countries. However, the European legal framework of the European Medicines Agency (EMA) for herbal medicine currently does not consider the use of many herbal drugs in children and adolescents because of an obvious lack of data. Many herbal monographs published by the competent scientific committee of the EMA (HMPC) restrict the use of HMPs to ages 12 or even 18 years and up. Thus, in many countries, HMPs lack adequate dosage recommendations for children.

Publication History

Article published online:
09 October 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany